MAYO CLINIC
Mayo Medical Laboratories

REFERENCE VALUES CHANGE
NOTIFICATION DATE: January 28, 2011
EFFECTIVE DATE: March 1, 2011

PROSTATE-SPECIFIC ANTIGEN (PSA), TOTAL AND FREE, SERUM #81944

EXPLANATION: Effective March 1, 2011, there will be a platform change from Beckman Coulter Unicel DXI 800 to Roche COBAS for Prostate-Specific Antigen (PSA), Total and Free, Serum (#81944). This change will require reference values changes.

CURRENT REFERENCE VALUES:
PSA >4 ng/mL and free PSA/total PSA ratio <0.25 indicates increased risk of prostate cancer.
PSA <4 ng/mL and free PSA/total PSA ratio <0.18 indicates increased risk of prostate cancer.
Free/total PSA ratios have been reported to be of value for evaluating men with total PSA values between 4 and 10 ng/mL. For men with PSA in this range, those with a free PSA ratio < or =0.10 have a risk for prostate cancer approximately double those with a free PSA ratio >0.24. When total PSA concentration is <4.0 ng/mL, the risk of prostate cancer is less and the use of free PSA ratios to clarify relative risk is not well defined, but lower free PSA ratios may be seen in the absence of cancer. When total PSA concentration is >10 ng/mL, the risk of prostate cancer is relatively high and the use of free PSA ratio again is not well defined, but cancer may be present even when the free PSA ratio is >0.24.
Serum markers are not specific for malignancy, and values may vary by method.

NEW REFERENCE VALUES:
Males:
Total PSA:

Age (Years)	PSA Upper Limit (ng/mL)
<40	< or =2.0
40-49	< or =2.5
50-59	< or =3.5
60-69	< or =4.5
70-79	< or =6.5
> or =80	< or =7.2

Free PSA:
When total PSA is in the range of 4.0-10.0 ng/mL, a free:total PSA ratio < or =0.10 indicates 49% to 65% risk of prostate cancer depending on age; a free:total PSA ratio >0.25 indicates a 9% to 16% risk of prostate cancer, depending on age

Females:
Not applicable

QUESTIONS: Contact your Mayo Medical Laboratories' Regional Manager
Greg Renkly, Mayo Medical Laboratories' Technologist Support
Telephone: 800-533-1710